MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

26.26 +0.37 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioNTech Stock Got A IBD RS Rating Lift ↗
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NASDAQ:CPRX is an undervalued gem with solid fundamentals. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
A Peek at Catalyst Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
NASDAQ:CPRX, a growth stock which is not overvalued. ↗
NASDAQ:CPRX is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Vericel Stock Sees RS Rating Shoot Higher ↗
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:CPRX is showing good growth, while it is not too expensive. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Biotech Momentum Trades For The Q4 Rally ↗
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
News headline image
NASDAQ:CPRX—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
Exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
News headline image
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX. ↗
While growth is established for CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Biotech Breakout Will Be Led By Small Caps ↗
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
News headline image
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
News headline image
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
News headline image
Biohaven Stock Earns Relative Strength Rating Upgrade ↗
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Investors should take notice of NASDAQ:CPRX—it offers a great deal for the fundamentals it presents. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank. ↗
Don't overlook CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story